NCT03964376View on ClinicalTrials.gov

Nasal High Flow Therapy in Surgical Patients with Unrecognized Obstructive Sleep Apnea

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

January 8, 2025

Study Completion Date

January 8, 2025

Conditions
Obstructive Sleep ApneaSleep Disordered Breathing
Interventions
OTHER

Nasal High Flow

Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute

OTHER

Usual Care

Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask

Trial Locations (8)

M5B 1W8

St. Michael's Hospital, Toronto

M5G 2C4

Toronto General Hospital, Toronto

M5T2S8

Toronto Western Hopsital, Dept. of Anesthesia, Toronto

Unknown

Prince of Wales Hospital, Hong Kong

Hospital Kuala Lumpur, Kuala Lumpur

University Malaya Medical Centre, Kuala Lumpur

Khoo Teck Puat Hospital, Singapore

Singapore General Hospital, Singapore

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03964376 - Nasal High Flow Therapy in Surgical Patients with Unrecognized Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter